Lannett Co. Inc. (LCI)

12.85
0.30 2.30
NYSE : Health Technology
Prev Close 13.15
Open 13.15
Day Low/High 12.78 / 13.25
52 Wk Low/High 12.15 / 30.35
Volume 111.58K
Avg Volume 676.90K
Exchange NYSE
Shares Outstanding 38.01M
Market Cap 477.08M
P/E Ratio 6.21
Div & Yield N.A. (N.A)

Latest News

Lannett Receives FDA Approval For Levofloxacin Oral Solution; Imminent Launch Anticipated

Lannett Receives FDA Approval For Levofloxacin Oral Solution; Imminent Launch Anticipated

PHILADELPHIA, June 1, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.

July 20th Options Now Available For Lannett (LCI)

Investors in Lannett Co., Inc. saw new options begin trading today, for the July 20th expiration.

Oversold Conditions For Lannett (LCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of December 21st Options Trading For Lannett (LCI)

Investors in Lannett Co., Inc. saw new options begin trading this week, for the December 21st expiration.

Commit To Buy Lannett At $12.50, Earn 18.4% Annualized Using Options

Commit To Buy Lannett At $12.50, Earn 18.4% Annualized Using Options

Investors considering a purchase of Lannett Co., Inc. stock, but cautious about paying the going market price of $16.55/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Relative Strength Alert For Lannett

Relative Strength Alert For Lannett

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of April 20th Options Trading For Lannett (LCI)

First Week of April 20th Options Trading For Lannett (LCI)

Investors in Lannett Co., Inc. saw new options begin trading this week, for the April 20th expiration.

First Week of LCI September 21st Options Trading

First Week of LCI September 21st Options Trading

Investors in Lannett Co., Inc. saw new options become available this week, for the September 21st expiration.

Lannett Enters Oversold Territory (LCI)

Lannett Enters Oversold Territory (LCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Lannett Company, Inc. (LCI) On Behalf Of Shareholders

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Lannett Company, Inc. (LCI) On Behalf Of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Lannett Company, Inc.

Scott+Scott, Attorneys At Law, LLP Is Investigating Derivative Claims On Behalf Of Shareholders Of Lannett Company, Inc.

Scott+Scott, Attorneys At Law, LLP Is Investigating Derivative Claims On Behalf Of Shareholders Of Lannett Company, Inc.

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether certain directors and officers of Lannett Company, Inc.

Lannett Reaches Analyst Target Price

Lannett Reaches Analyst Target Price

In recent trading, shares of Lannett Co., Inc. have crossed above the average analyst 12-month target price of $26.30, changing hands for $27.50/share.

Noteworthy Tuesday Option Activity: LCI, OFG, LAMR

Noteworthy Tuesday Option Activity: LCI, OFG, LAMR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lannett Co., Inc. , where a total of 29,266 contracts have traded so far, representing approximately 2.9 million underlying shares.

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Lannett (LCI) Shares Cross Above 200 DMA

Lannett (LCI) Shares Cross Above 200 DMA

In trading on Monday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $20.67, changing hands as high as $20.90 per share.

Small Caps Continue to Outperform on Tax Reform, Oil Marches Higher - ICYMI

Small Caps Continue to Outperform on Tax Reform, Oil Marches Higher - ICYMI

Here's what you need to know now for Wednesday, Sept. 27.

Notable Wednesday Option Activity: LCI, PTCT, ACTA

Notable Wednesday Option Activity: LCI, PTCT, ACTA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lannett Co., Inc. , where a total of 4,873 contracts have traded so far, representing approximately 487,300 underlying shares.

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.

Teva, Mylan Seen to Stay on M&A Sidelines

Teva, Mylan Seen to Stay on M&A Sidelines

Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila.

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva's Massive Debt Load Just Became an Even Bigger Issue

It is just not going to get better anytime soon.

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva's stock is crumbling as another analyst slams it with a downgrade.

Relative Strength Alert For Lannett

Relative Strength Alert For Lannett

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Bullish Two Hundred Day Moving Average Cross - LCI

Bullish Two Hundred Day Moving Average Cross - LCI

In trading on Friday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $22.22, changing hands as high as $22.70 per share.

Oversold Conditions For Lannett (LCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Commit To Purchase Lannett At $15, Earn 10.7% Annualized Using Options

Investors considering a purchase of Lannett Co., Inc. stock, but cautious about paying the going market price of $20.00/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Rating: C (Hold)